Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Maximum Days for Report Obtainment: The report for the FGFRs Mutation Analysis Test by NGS can be obtained within a maximum of 14 business days from the date of sample receipt.

What are the prerequisites for the test FGFRs Mutation Analysis Test by NGS

  • Specimen: Formalin-fixed, paraffin-embedded tissue block
  • Minimum Tumor Content: 20%
  • Minimum Tumor Area: 5mm
  • Requisition Form: Completed and submitted with the specimen
  • Clinical History: Including relevant information about the patient's diagnosis and treatment

What are the measure values for the test FGFRs Mutation Analysis Test by NGS

  1. Presence of FGFR gene mutations
  2. Percentage of mutation allele frequency
  3. Classification of mutations as pathogenic or benign
  4. Comparison of mutation profile with known databases

What does this test FGFRs Mutation Analysis Test by NGS identify?

  • Identifies mutations in FGFR genes
  • Specifically targets FGFR1, FGFR2, FGFR3, and FGFR4 genes
  • Utilizes Next Generation Sequencing (NGS) technology for high-throughput analysis
  • Helps in determining the presence of activating mutations in FGFRs
  • Aids in personalized treatment decisions for patients with FGFR-related cancers

Why is this test FGFRs Mutation Analysis Test by NGS taken?

The FGFRs Mutation Analysis Test by NGS is taken to identify mutations in the FGFR (Fibroblast Growth Factor Receptor) genes. These mutations can play a role in various cancers, including lung cancer, bladder cancer, and certain types of bone cancer. By analyzing the FGFR genes using Next Generation Sequencing (NGS) technology, healthcare providers can determine the specific mutations present in a patient's tumor.

No FAQs available.

Customer Google Rating